Related references
Note: Only part of the references are listed.Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Friederike Holze et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
Friederike Holze et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Albert Garcia-Romeu et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials
Michael C. Mithoefer et al.
PSYCHOPHARMACOLOGY (2019)
A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy
Ben Sessa et al.
FRONTIERS IN PSYCHIATRY (2019)
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors
Roland R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
Long-lasting subjective effects of LSD in normal subjects
Yasmin Schmid et al.
PSYCHOPHARMACOLOGY (2018)
Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects
Patrick C. Dolder et al.
PSYCHOPHARMACOLOGY (2018)
Psychedelics and connectedness
R. L. Carhart-Harris et al.
PSYCHOPHARMACOLOGY (2018)
High dose psilocybin is associated with positive subjective effects in healthy volunteers
Christopher R. Nicholas et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial
Michael C. Mithoefer et al.
LANCET PSYCHIATRY (2018)
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Matthias E. Liechti et al.
PSYCHOPHARMACOLOGY (2017)
Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution
Raphael Milliere
FRONTIERS IN HUMAN NEUROSCIENCE (2017)
Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies
Kim P. C. Kuypers et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
Safety pharmacology of acute MDMA administration in healthy subjects
Patrick Vizeli et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation
Katrin H. Preller et al.
CURRENT BIOLOGY (2017)
The role of the serotonin 2A receptor in the fabric and modulation of personal meaning in lysergic acid diethylamide (LSD)-induced states
K. H. Preller et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Anna Rickli et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy
Timothy Amoroso et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality
Patrick C. Dolder et al.
NEUROPSYCHOPHARMACOLOGY (2016)
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Robin L. Carhart-Harris et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L. Carhart-Harris et al.
LANCET PSYCHIATRY (2016)
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Yasmin Schmid et al.
BIOLOGICAL PSYCHIATRY (2015)
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Frederick S. Barrett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Michael P. Bogenschutz et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report
Flavia de L. Osorio et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2015)
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects
Peter Gasser et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Interactions between Bupropion and 3,4-Methylenedioxymethamphetamine in Healthy Subjects
Yasmin Schmid et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination
Cedric M. Hysek et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
Peter Gasser et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2014)
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
Matthew W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Differential effects of MDMA and methylphenidate on social cognition
Yasmin Schmid et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
MDMA enhances emotional empathy and prosocial behavior
Cedric M. Hysek et al.
SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE (2014)
The Potential Dangers of Using MDMA for Psychotherapy
Andrew C. Parrott
JOURNAL OF PSYCHOACTIVE DRUGS (2014)
α1-Adrenergic Receptors Contribute to the Acute Effects of 3,4-Methylenedioxymethamphetamine in Humans
Cedric M. Hysek et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2013)
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study
Michael C. Mithoefer et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2013)
Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans
C. M. Hysek et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Teri S. Krebs et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Prediction of Psilocybin Response in Healthy Volunteers
Erich Studerus et al.
PLOS ONE (2012)
Duloxetine Inhibits Effects of MDMA (Ecstasy) In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study
Cedric M. Hysek et al.
PLOS ONE (2012)
Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin
Katherine A. MacLean et al.
JOURNAL FOR THE SCIENTIFIC STUDY OF RELIGION (2012)
Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner
Michael Lyvers et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2012)
Effects of the α2-Adrenergic Agonist Clonidine on the Pharmacodynamics and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Healthy Volunteers
Cedric M. Hysek et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Charles S. Grob et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (Ecstasy) in Humans
C. M. Hysek et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
The safety and efficacy of ± 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study
Michael C. Mithoefer et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
Katherine A. MacLean et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Roland R. Griffiths et al.
PSYCHOPHARMACOLOGY (2011)
OPINION The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Franz X. Vollenweider et al.
NATURE REVIEWS NEUROSCIENCE (2010)
Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV)
Erich Studerus et al.
PLOS ONE (2010)
Effects of MDMA on sociability and neural response to social threat and social reward
Gillinder Bedi et al.
PSYCHOPHARMACOLOGY (2009)
LSD-assisted psychotherapy in persons suffering from anxiety associated with advanced-stage life threatening diseases. A phase-II, double-blind, placebo-controlled dose-response pilot study
Torsten Passie et al.
CNS NEUROSCIENCE & THERAPEUTICS (2008)
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
R. R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval
Franz X. Vollenweider et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Francisco A. Moreno et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
R. R. Griffiths et al.
PSYCHOPHARMACOLOGY (2006)
Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study
F Hasler et al.
PSYCHOPHARMACOLOGY (2004)
Gender differences in the subjective effects of MDMA
ME Liechti et al.
PSYCHOPHARMACOLOGY (2001)
Psychological and physiological effects of MDMA (ecstasy) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans
ME Liechti et al.
NEUROPSYCHOPHARMACOLOGY (2000)
Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) are attenuated by the serotonin uptake inhibitor citalopram
ME Liechti et al.
NEUROPSYCHOPHARMACOLOGY (2000)
Share Paper
